Used in research and development for targeting TMEM16A (ANO1), a calcium-activated chloride channel involved in various physiological and pathological processes. This reference antibody is instrumental in studying diseases where ANO1 is overexpressed, such as certain cancers (e.g., head and neck squamous cell carcinoma, gastrointestinal stromal tumors), cystic fibrosis, and chronic obstructive pulmonary disease (COPD). It enables precise detection and quantification of the target protein in cellular and tissue samples, supporting drug discovery efforts, especially in validating therapeutic candidates that modulate ANO1 activity. Due to its origin from a Novartis patent, it may also serve as a benchmark in developing biosimilars or competitive inhibitors.